1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Omega Fund Management (US) Inc. Buys Gossamer Bio Inc, Replimune Group Inc, Translate Bio Inc, Sells Kezar Life Sciences Inc, Egalet Corp

Boston, MA, based Investment company Omega Fund Management (US) Inc. buys Gossamer Bio Inc, Replimune Group Inc, Translate Bio Inc, Paratek Pharmaceuticals Inc, CymaBay Therapeutics Inc, FibroGen Inc, Cidara Therapeutics Inc, ESSA Pharma Inc, Jounce Therapeutics Inc, Pieris Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Sienna Biopharmaceuticals Inc, sells Kezar Life Sciences Inc, Egalet Corp during the 3-months ended 2019Q1, according to the most recent filings of the investment company, Omega Fund Management (US) Inc.. As of 2019Q1, Omega Fund Management (US) Inc. owns 1 stocks with a total value of $13 million. These are the details of the buys and sells.

For the details of Omega Fund Management (US) Inc.'s stock buys and sells, go to https://www.gurufocus.com/guru/omega+fund+management+%28us%29+inc./current-portfolio/portfolio

These are the top 5 holdings of Omega Fund Management (US) Inc.
  1. Replimune Group Inc (REPL) - 10,206,910 shares, 32.73% of the total portfolio. Shares added by 100.00%
  2. Gossamer Bio Inc (GOSS) - 6,953,416 shares, 31.85% of the total portfolio. New Position
  3. Translate Bio Inc (TBIO) - 4,875,206 shares, 10.50% of the total portfolio. Shares added by 100.00%
  4. Paratek Pharmaceuticals Inc (PRTK) - 5,200,820 shares, 5.89% of the total portfolio. Shares added by 100.00%
  5. CymaBay Therapeutics Inc (CBAY) - 1,102,954 shares, 3.10% of the total portfolio. Shares added by 100.00%
New Purchase: Gossamer Bio Inc (GOSS)

Omega Fund Management (US) Inc. initiated holding in Gossamer Bio Inc. The purchase prices were between $17.58 and $23.97, with an estimated average price of $20.81. The stock is now traded at around $20.98. The impact to a portfolio due to this purchase was 31.85%. The holding were 6,953,416 shares as of .

Added: Replimune Group Inc (REPL)

Omega Fund Management (US) Inc. added to a holding in Replimune Group Inc by 100.00%. The purchase prices were between $10 and $16.24, with an estimated average price of $12.42. The stock is now traded at around $14.76. The impact to a portfolio due to this purchase was 16.37%. The holding were 10,206,910 shares as of .

Added: Translate Bio Inc (TBIO)

Omega Fund Management (US) Inc. added to a holding in Translate Bio Inc by 100.00%. The purchase prices were between $4.9 and $10.23, with an estimated average price of $7.66. The stock is now traded at around $10.02. The impact to a portfolio due to this purchase was 5.25%. The holding were 4,875,206 shares as of .

Added: Paratek Pharmaceuticals Inc (PRTK)

Omega Fund Management (US) Inc. added to a holding in Paratek Pharmaceuticals Inc by 100.00%. The purchase prices were between $5.13 and $7.24, with an estimated average price of $6.45. The stock is now traded at around $4.55. The impact to a portfolio due to this purchase was 2.95%. The holding were 5,200,820 shares as of .

Added: CymaBay Therapeutics Inc (CBAY)

Omega Fund Management (US) Inc. added to a holding in CymaBay Therapeutics Inc by 100.00%. The purchase prices were between $7.87 and $13.42, with an estimated average price of $10.56. The stock is now traded at around $12.62. The impact to a portfolio due to this purchase was 1.55%. The holding were 1,102,954 shares as of .

Added: FibroGen Inc (FGEN)

Omega Fund Management (US) Inc. added to a holding in FibroGen Inc by 100.00%. The purchase prices were between $42.83 and $59.91, with an estimated average price of $54.17. The stock is now traded at around $35.77. The impact to a portfolio due to this purchase was 1.5%. The holding were 261,292 shares as of .

Added: Cidara Therapeutics Inc (CDTX)

Omega Fund Management (US) Inc. added to a holding in Cidara Therapeutics Inc by 100.00%. The purchase prices were between $2.35 and $3.27, with an estimated average price of $2.74. The stock is now traded at around $2.02. The impact to a portfolio due to this purchase was 0.85%. The holding were 3,017,588 shares as of .

Sold Out: Kezar Life Sciences Inc (KZR)

Omega Fund Management (US) Inc. sold out a holding in Kezar Life Sciences Inc. The sale prices were between $16.83 and $23.75, with an estimated average price of $19.82.

Sold Out: Egalet Corp (EGLTQ)

Omega Fund Management (US) Inc. sold out a holding in Egalet Corp. The sale prices were between $0 and $0.01, with an estimated average price of $0.01.



Here is the complete portfolio of Omega Fund Management (US) Inc.. Also check out:

1. Omega Fund Management (US) Inc.'s Undervalued Stocks
2. Omega Fund Management (US) Inc.'s Top Growth Companies, and
3. Omega Fund Management (US) Inc.'s High Yield stocks
4. Stocks that Omega Fund Management (US) Inc. keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK